But drug did not reduce disease progression in COV-BARRIER trial Treatment of hospitalized Covid-19 patients with the selective Janus kinase (JAK) inhibitor baricitinib, along with standard of care including dexamethasone, was associated with reduced mortality but not reduction in disease progression in the international, multicenter, phase III COV-BARRIER randomized trial. Baricitinib plus standard of care
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
A "brain organoid" model using human cells matches molecular and pharmacological aspects of fragile X syndrome more closely than mouse versions, Emory.
NIH awards Emory and partners $27 6M for pediatric HIV cure research emory.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emory.edu Daily Mail and Mail on Sunday newspapers.
Nurse Anesthetist Association Name Change Provokes Criticism medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.